DE1695907C3 - Verwendung von 3,5-Dimethyl-l,2oxazinon-(6) - Google Patents
Verwendung von 3,5-Dimethyl-l,2oxazinon-(6)Info
- Publication number
- DE1695907C3 DE1695907C3 DE1967T0035128 DET0035128A DE1695907C3 DE 1695907 C3 DE1695907 C3 DE 1695907C3 DE 1967T0035128 DE1967T0035128 DE 1967T0035128 DE T0035128 A DET0035128 A DE T0035128A DE 1695907 C3 DE1695907 C3 DE 1695907C3
- Authority
- DE
- Germany
- Prior art keywords
- dimethyl
- oxazinone
- product
- insomnia
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 9
- 206010022437 insomnia Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 7
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 5
- 229960004815 meprobamate Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- YUICRCSHEOZHST-UHFFFAOYSA-N 2-methyl-4-oxopent-2-enoic acid Chemical compound CC(=O)C=C(C)C(O)=O YUICRCSHEOZHST-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/215—Saturated compounds having only one carboxyl group and containing keto groups containing singly bound oxygen containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR81953A FR5948M (show.php) | 1966-10-28 | 1966-10-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1695907A1 DE1695907A1 (de) | 1971-05-06 |
| DE1695907B2 DE1695907B2 (de) | 1978-08-03 |
| DE1695907C3 true DE1695907C3 (de) | 1979-04-05 |
Family
ID=8620138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1967T0035128 Expired DE1695907C3 (de) | 1966-10-28 | 1967-10-27 | Verwendung von 3,5-Dimethyl-l,2oxazinon-(6) |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE705478A (show.php) |
| DE (1) | DE1695907C3 (show.php) |
| FR (1) | FR5948M (show.php) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4936512B2 (ja) * | 2006-02-24 | 2012-05-23 | 公立大学法人大阪府立大学 | 光解裂性環状化合物 |
-
1966
- 1966-10-28 FR FR81953A patent/FR5948M/fr not_active Expired
-
1967
- 1967-10-23 BE BE705478D patent/BE705478A/fr not_active IP Right Cessation
- 1967-10-27 DE DE1967T0035128 patent/DE1695907C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1695907B2 (de) | 1978-08-03 |
| FR5948M (show.php) | 1968-04-16 |
| BE705478A (show.php) | 1968-03-01 |
| DE1695907A1 (de) | 1971-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE1695907C3 (de) | Verwendung von 3,5-Dimethyl-l,2oxazinon-(6) | |
| DE69907387T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis. | |
| DE2451933C2 (show.php) | ||
| DE2416339C3 (de) | Argininpyroglutaniat, Verfahren zu seiner Herstellung und Arzneimittel | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| EP0024258A1 (de) | Die Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Herpes-Infektionen | |
| CH634302A5 (de) | Verfahren zur herstellung neuer mercaptomethylpyridin-derivate. | |
| DE3887426T2 (de) | Eperisone als Hypotonikum. | |
| DE3321772A1 (de) | Pyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel | |
| DE69214647T2 (de) | Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz | |
| DE2521905C2 (de) | Arzneimittel zur cerebralen Durchblutungsförderung | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2036633A1 (de) | Arzneimittel mit entzündungshemmender, analgetischer und antipyretischer Wirksam | |
| DE2615694A1 (de) | Pharmazeutische zusammensetzungen | |
| DE2345291A1 (de) | Therapeutisches mittel | |
| DE69025272T2 (de) | Therapeutisches Mittel für Erkrankungen des Zentralnervensystems | |
| EP1244442B1 (de) | Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen | |
| DE2131626A1 (de) | 3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| DE1940192C3 (de) | Reserpinderivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate | |
| DE2030932C3 (de) | Arzneimittel zur oralen Behandlung von Oxalatsteinen | |
| AT335469B (de) | Verfahren zur herstellung des neuen 4-(n-propyl)-n-heptanol-3-carbamates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |